To: All Health Facilities - Private Sector in Dubai

In accordance with the recommendations of the Ministry of Health and Prevention and interest to maintain community and public health safety, we would like to draw your attention to the following safety alerts and warnings for August 2018:

1. Warning about the use of the pharmaceuticals products (TECENTRIQ) atezolizumab.
2. Warning on the antibiotics group product Fluoroquinolones.
3. Withdrawal of two batches of the pharmaceutical product Leflocad (Levofloxacin500 mg) Tablets manufactured by Jubilant Generics limited and distributed by the Authorized agent Beta Star Trading LLC.
4. Withdrawal of the pharmaceutical product Mebzol 100mg Tablets manufactured by Julphar.
5. Suspension on registration of the pharmaceutical product Glynase 5mg Tablets manufactured by Julphar.
6. Warning for dietary/medical products Nature Plus Vitamin A 10,000 IU.
7. Warning on the use of the slimming product Optrimax Jelly mixed Green Tea and Inulin Jelly with Blueberry Juice.
8. Medical Device withdraw of (Transvaginal Mesh) for all companies.

9. Medical Safety Alerts on the medical products Homeopathic spray, Weight Away Remedy manufactured by Well Remedies LLC sold through the internet.

10. Medical Device Safety Alert Warnings on Leukotrap RC System with RC2D Filter By American company Haemonetics Manufacturing Inc.

For more information on the above safety alert, and to keep up to date with safety alerts please visit MOHAP website:


- To report Adverse Drug Reaction (ADR) or Event, kindly go through the (ADR) Electronic link Reporting available at the website:
  http://www.mohap.gov.ae/ar/services/Pages/406.aspx

Or from the smart application UAE RADR

Or contact the following addresses:
Tel: 04-2301448 or fax 04-2301947 or Email: pv@moh.gov.ae

- To avoid any violations or penalties all health facilities must adhere to this Circular in accordance with the instructions set out within and should not use the mentioned Lot/Batch Number if available.

- In case of any adverse events, report via the reporting link available at the website:
  http://www.mohap.gov.ae/ar/services/Pages/406.aspx

Or from the smart application UAE RADR

Or contact the following addresses:
Tel: 04-2301448 or fax 04-2301947 or Email: pv@moh.gov.ae

- To report Adverse Drug Reaction (ADR) or Event, kindly go through the (ADR) Electronic link Reporting available at the website:
  http://www.mohap.gov.ae/ar/services/Pages/406.aspx

Or from the smart application UAE RADR

Or contact the following addresses:
Tel: 04-2301448 or fax 04-2301947 or Email: pv@moh.gov.ae

- To avoid any violations or penalties all health facilities must adhere to this Circular in accordance with the instructions set out within and should not use the mentioned Lot/Batch Number if available.

For more information on the above safety alert, and to keep up to date with safety alerts please visit MOHAP website:


- To report Adverse Drug Reaction (ADR) or Event, kindly go through the (ADR) Electronic link Reporting available at the website:
  http://www.mohap.gov.ae/ar/services/Pages/406.aspx

Or from the smart application UAE RADR

Or contact the following addresses:
Tel: 04-2301448 or fax 04-2301947 or Email: pv@moh.gov.ae

- To avoid any violations or penalties all health facilities must adhere to this Circular in accordance with the instructions set out within and should not use the mentioned Lot/Batch Number if available.

For more information on the above safety alert, and to keep up to date with safety alerts please visit MOHAP website:


- To report Adverse Drug Reaction (ADR) or Event, kindly go through the (ADR) Electronic link Reporting available at the website:
  http://www.mohap.gov.ae/ar/services/Pages/406.aspx

Or from the smart application UAE RADR

Or contact the following addresses:
Tel: 04-2301448 or fax 04-2301947 or Email: pv@moh.gov.ae

- To avoid any violations or penalties all health facilities must adhere to this Circular in accordance with the instructions set out within and should not use the mentioned Lot/Batch Number if available.
For more information, kindly contact the call center on:
Telephone: 800-342
Email address: regulation@dha.gov.ae

With Regards, Health Regulation Sector

Dr. Marwan Mohd Al Mulla
CEO of the Health Regulation Sector – DHA